Stool-based tests like FIT and stool DNA have made initial colorectal cancer screening easier than ever. However, nearly half of patients with positive results fail to complete their follow-up colonoscopy within a year, driven primarily by bowel prep dread. This post examines real-world care gaps, the 1.8 times higher cancer risk of stalled care, and how Zera Medical is working to bridge these two vital steps.

GLP-1 medications like Ozempic and semaglutide are now used by roughly 1 in 8 US adults, concentrated in the exact 50 to 64 age range colorectal cancer screening targets. New research shows GLP-1 users face more than double the odds of inadequate bowel preparation, and clinical guidance on how to manage it is still catching up. This post breaks down the scale of GLP-1 adoption, what the data shows about its effect on prep quality, and how Zera Medical is rethinking the prep process for patients the standard approach has never served well.

A colonoscopy is only as good as the prep that comes before it, and up to a third of procedures are compromised by inadequate bowel preparation before the scope is ever advanced. This post breaks down what that failure actually costs: missed lesions, repeat procedures, destabilized clinic schedules, and real erosion in screening economics. It makes the case that inadequate prep is a structural problem built into the at-home model, not a patient failure, and points to ZeraFlow as a clinic-based way to fix it at the source.